| [1] |
Lorger M, Felding-Habermann B.Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis[J].Am J Pathol,2010,176(6):2958-2971.
|
| [2] |
Lin NU, Amiri-Kordestani L, Palmieri D, et al.CNS metastases in breast cancer: old challenge, new frontiers[J].Clin Cancer Res,2013,19(23):6404-6418.
|
| [3] |
Lombardi G, Di Stefano AL, Farina P, et al.Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature[J].Cancer Treat Rev,2014,40(8):951-959.
|
| [4] |
Singh R,Gupta S,Pawar SB,et al.Evaluation of ER,PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India[J].J Cancer Res Ther,2014,10(1):26-28.
|
| [5] |
Verma S, Joy AA, Rayson D, et al.HER story: the next chapter in HER-2-directed therapy for advanced breast cancer[J].Oncologist,2013,18(11):1153-1166.
|
| [6] |
Mitrovic O, Cokic V, Dikic D, et al.Correlation between ER,PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer[J].Target Oncol,2013,9(4):367-379.
|
| [7] |
Jorns JM, Healy P, Zhao L.Review of estrogen receptor,progesterone receptor, and HER-2/neu immunohistochemistry impacts on treatment for a small subset of breast cancer patients transferring care to another institution[J].Arch Pathol Lab Med,2013,137(11):1660-1663.
|
| [8] |
Lee LJ, Alexander B, Schnitt SJ, et al.Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers[J].Cancer,2011,117(14):3093-3100.
|
| [9] |
Tripsianis G, Papadopoulou E, Romanidis K, et al.Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2,IL-6, TNF-alpha and TGF-beta1[J].Asian Pac J Cancer Prev,2013,14(11):6813-6820.
|
| [10] |
Thriveni K, Deshmane V, Ramaswamy G, et al.Diagnostic significance of CA15-3 with combination of HER-2/neu values at 85th percentiles in breast Cancer [J].Indian J Clin Biochem,2013,28(2):136-140.
|
| [11] |
Robins HI, O'Neill A, Mehta M, et al.A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT & SRS with temozolomide or erlotinib for nonsmall cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320: in regard to Sperduto et al[J].Int J Radiat Oncol Biol Phys,2013,86(5):809-810.
|
| [12] |
Sperduto PW, Wang M, Robins HI, et al.A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for nonsmall cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320[J].Int J Radiat Oncol Biol Phys,2013,85(5):1312-1318.
|
| [13] |
Weiss SE, Kelly PJ.Neurocognitive function after WBRT plus SRS or SRS alone[J].Lancet Oncol,2010,11(3):220-221.
|
| [14] |
Rades D, Kueter JD, Hornung D, et al.Comparison of stereotactic radiosurgery ( SRS ) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS)for one to three brain metastases[J].Strahlenther Onkol,2008,184(12):655-662.
|
| [15] |
Rades D, Kueter JD, Veninga T, et al.Whole brain radiotherapy plus stereotactic radiosurgery (WBRT + SRS)versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: results of a matched pair analysis[J].Eur J Cancer,2009,45(3):400-404.
|
| [16] |
Lin NU.Targeted therapies in brain metastases[J].Curr Treat Options Neurol,2014,16(1):276.
|
| [17] |
Bachelot T, Le Rhun E, Labidi-Gally I, et al.Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies[J].Bull Cancer, 2013,100(1):7-14.
|
| [18] |
Lim E, Lin NU.New insights and emerging therapies for breast cancer brain metastases[J].Oncology (Williston Park),2012,26(7):652-659,663.
|
| [19] |
Peereboom DM, Murphy C, Ahluwalia MS, et al.Phase Ⅱtrial of patupilone in patients with brain metastases from breast cancer[J].Neuro Oncol,2014,16(4):579-583.
|
| [20] |
Regina A, Demeule M, Che C, et al.Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2 [ J].Br J Pharmacol, 2008,155(2):185-197.
|
| [21] |
Thomas FC, Taskar K, Rudraraju V, et al.Uptake of ANG1005, a novel paclitaxel derivative, through the bloodbrain barrier into brain and experimental brain metastases of breast cancer[J].Pharm Res,2009,26(11):2486-2494.
|
| [22] |
Palmieri D, Bronder JL, Herring JM, et al.Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain[J].Cancer Res,2007,67(9):4190-4198.
|
| [23] |
Kennecke H, Yerushalmi R, Woods R, et al.Metastatic behavior of breast cancer subtypes[J].J Clin Oncol, 2010,28(20):3271-3277.
|
| [24] |
Leyland-Jones B.Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases[J].J Clin Oncol,2009,27(31):5278-5286.
|
| [25] |
Swain SM, Im YH, Im SA, et al.Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase Ⅲtrial CLEOPATRA[J].Oncologist,2014,19(7):693-701.
|
| [26] |
Neugut AI, Hillyer GC, Kushi LH, et al.Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer[J].Breast Cancer,2014,21(6):780-785.
|
| [27] |
Chiba A, Shimizu S, Yoshida A, et al.Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer[J].Gan To Kagaku Ryoho, 2012,39(11):1675-1679.
|
| [28] |
Cetin B, Benekli M, Oksuzoglu B, et al.Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology(ASMO) experience[J].Onkologie,2012,35(12):740-745.
|
| [29] |
Kaplan MA, Isikdogan A, Koca D, et al.Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology[J].Breast Cancer,2013,21(6):677-683.
|
| [30] |
Bachelot T, Romieu G, Campone M, et al.Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer(LANDSCAPE): a single-group phase 2 study[J].Lancet Oncol,2013,14(1):64-71.
|
| [31] |
Bartolotti M, Franceschi E, Brandes AA.Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts[J].Future Oncol,2013,9(11):1653-1664.
|
| [32] |
Sambade MJ, Kimple RJ, Camp JT, et al.Lapatinib in combination with radiation diminishes tumor regrowth in HER2+and basal-like/EGFR + breast tumor xenografts[J].Int J Radiat Oncol Biol Phys,2010,77(2):575-581.
|
| [33] |
Zhang X, Munster PN.New protein kinase inhibitors in breast cancer: afatinib and neratinib[J].Expert Opin Pharmacother,2014,15(9):1277-1288.
|
| [34] |
Canonici A, Gijsen M, Mullooly M, et al.Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer[J].Oncotarget,2013,4(10):1592-1605.
|
| [35] |
Lopez-Tarruella S, Jerez Y, Marquez-Rodas I, et al.Neratinib(HKI-272) in the treatment of breast cancer[J].Future Oncol,2012,8(6):671-681.
|
| [36] |
Gore ME, Szczylik C, Porta C, et al.Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expandedaccess trial[J].Lancet Oncol,2009,10(8):757-763.
|
| [37] |
Socinski MA, Langer CJ, Huang JE, et al.Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases[J].J Clin Oncol,2009,27(31):5255-5261.
|
| [38] |
Besse B, Lasserre SF, Compton P, et al.Bevacizumab safety in patients with central nervous system metastases[J].Clin Cancer Res,2010,16(1):269-278.
|
| [39] |
De Braganca KC,Janjigian YY,Azzoli CG,et al.Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer[J].J Neurooncol,2010,100(3):443-447.
|
| [40] |
Kumler I, Christiansen OG, Nielsen DL.A systematic review of bevacizumab efficacy in breast cancer[J].Cancer Treat Rev,2014,40(8):960-973.
|
| [41] |
Adamo B, Deal AM, Burrows E, et al.Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases[J].Breast Cancer Res,2011,13(6):R125.
|
| [42] |
Bendell JC, Rodon J, Burris HA, et al.Phase I, doseescalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors[J].J Clin Oncol,2012,30(3):282-290.
|
| [43] |
Tabchy A, Ma CX, Bose R, et al.Incorporating genomics into breast cancer clinical trials and care[J].Clin Cancer Res,2013,19(23):6371-6379.
|
| [44] |
Nanni P, Nicoletti G,Palladini A,et al.Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor[J].PLoS One,2012,7(6):e39626.
|
| [45] |
Bos PD, Zhang XH,Nadal C,et al.Genes that mediate breast cancer metastasis to the brain[J].Nature,2009,459(7249):1005-1009.
|
| [46] |
Minn AJ, Gupta GP, Siegel PM, et al.Genes that mediate breast cancer metastasis to lung[J].Nature, 2005,436(7050):518-524.
|
| [47] |
Kienast Y, von Baumgarten L, Fuhrmann M, et al.Real-time imaging reveals the single steps of brain metastasis formation[J].Nat Med,2010,16(1):116-122.
|
| [48] |
Neman J,Termini J,Wilczynski S,et al.Human breast cancer metastases to the brain display GABAergic properties in the neural niche[J].Proc Natl Acad Sci U S A, 2014,111(3):984-989.
|
| [49] |
Valiente M,Obenauf AC,Jin X,et al.Serpins promote cancer cell survival and vascular co-option in brain metastasis[J].Cell,2014,156(5):1002-1016.
|
| [50] |
Sofroniew MV, Vinters HV.Astrocytes: biology and pathology[J].Acta Neuropathol,2010,119(1):7-35.
|
| [51] |
Sim HW, Morris PG, Patil S, et al.Brain metastases in breast cancer[J].Expert Rev Anticancer Ther,2014,14(2):173-183.
|
| [52] |
Yoneda T,Williams PJ,Hiraga T,et al.A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro[J].J Bone Miner Res,2001,16(8):1486-1495.
|
| [53] |
Nakamura H, Hiraga T, Ninomiya T, et al.Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice[J].J Bone Miner Metab,2008,26(6):642-647.
|
| [54] |
Stark AM, Anuszkiewicz B, Mentlein R, et al.Differential expression of matrix metalloproteinases in brain- and boneseeking clones of metastatic MDA-MB-231 breast cancer cells[J].J Neurooncol,2007,81(1):39-48.
|
| [55] |
Zhang S, Huang WC, Zhang L, et al.SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases[J].Cancer Res,2013,73(18):5764-5774.
|
| [56] |
Gril B, Palmieri D, Bronder JL, et al.Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain[J].J Natl Cancer Inst,2008,100(15):1092-1103.
|
| [57] |
Fokas E, Steinbach JP, Rodel C.Biology of brain metastases and novel targeted therapies: time to translate the research[J].Biochim Biophys Acta,2013,1835(1):61-75.
|
| [58] |
Bicker J, Alves G, Fortuna A, et al.Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: A review[J].Eur J Pharm Biopharm,2014,87(3):409-432.
|
| [59] |
Nagpal K, Singh SK, Mishra DN.Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB[J].Expert Opin Drug Deliv,2013,10(7):927-955.
|